Loading...
•
Dec 31, 2021
Equillium Q4 2021 Earnings Report
Equillium reported financial results for the fourth quarter and full year 2021 and provided corporate and clinical development updates.
Key Takeaways
Equillium announced positive topline data from EQUATE study, initiated EQUATOR Phase 3 study, presented interim safety data from EQUALISE study, and acquired Bioniz Therapeutics. The company's clinical advancements were fueled by itolizumab, and the acquisition expands their pipeline.
Announced positive topline data from EQUATE study of itolizumab in first-line aGVHD.
Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD.
Presented interim safety data and reduction in proteinuria from the EQUALISE study of itolizumab in lupus patients.
Acquired Bioniz Therapeutics, adding two first-in-class clinical-stage assets to pipeline and proprietary product discovery platform.
Forward Guidance
Equillium anticipates several upcoming milestones and catalysts, including interim data from the EQUALISE Phase 1b study, initiation of a Phase 2 study for EQ101 in alopecia areata, and initiation of a Phase 1 study for EQ102 in celiac disease.
Positive Outlook
- Itolizumab - EQUALISE Phase 1b study: interim data from Type B patients (lupus nephritis) expected mid-2022
- EQ101 - Initiate Phase 2 study in alopecia areata expected 2H 2022
- EQ102 - Initiate Phase 1 study in celiac disease expected 2H 2022
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...